Journal of Clinical Respiratory Medicine

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Journal of Clinical Respiratory Medicine 44 7897 074717

Conference Proceedings - Journal of Clinical Respiratory Medicine (2025) Volume 9, Issue 1

Long-Term Outcomes of COVID-19-Induced Pulmonary Fibrosis: A Multi-Center Prospective Study

Christine Jenkins *

Respiratory and Sleep Medicine, University of New South Wales, Australia

*Corresponding Author:
Christine Jenkins
Respiratory and Sleep Medicine, University of New South Wales, Australia
E-mail: c.jenkins@unsw.edu.au

Received: 1-Mar-2025, Manuscript No. aajcrm-25-167787; Editor assigned: 4-Mar-2025, PreQC No. aajcrm-25-167787 (PQ) Reviewed:17-Mar-2025, QC No. aajcrm-25-167787Revised:24-Mar-2025, Manuscript No. aajcrm-25-167787; Published:31-Mar-2025, DOI: 10.35841/ aajcrm - 9.1.254

Citation: Jenkins C. Long-term outcomes of covid-19-induced pulmonary fibrosis: A multi-center prospective study. J Clin Resp Med. 2025;9(1):254

Visit for more related articles at Journal of Clinical Respiratory Medicine

Introduction

Pulmonary fibrosis has emerged as a critical long-term complication in patients recovering from moderate to severe COVID-19. This fibrotic lung disease, characterized by persistent inflammation and irreversible scarring, leads to progressive respiratory decline. The current multi-center prospective study aimed to assess the long-term pulmonary outcomes, functional status, and radiologic progression in patients diagnosed with COVID-19-induced pulmonary fibrosis over a 24-month follow-up period [1].

The study enrolled 580 patients from eight tertiary care hospitals across North America, Europe, and Asia, all of whom had confirmed SARS-CoV-2 infection and radiologic evidence of fibrotic changes within six months of acute illness. Patients underwent serial evaluations every six months, including pulmonary function tests (PFTs), high-resolution CT (HRCT) imaging, 6-minute walk tests, and quality-of-life assessments. At the 24-month mark, 38% of patients continued to exhibit reduced forced vital capacity (FVC), and 44% had persistent exertional dyspnea [2].

Notably, the extent of fibrosis and respiratory dysfunction strongly correlated with the initial severity of COVID-19 pneumonia. Patients who required intensive care or mechanical ventilation were more likely to have extensive fibrotic sequelae. Age above 60, pre-existing lung disease, smoking history, and elevated inflammatory markers (e.g., CRP, IL-6) during acute infection were also associated with worse outcomes. These findings underscore the need for early identification and monitoring of high-risk individuals [3].

Management strategies in these patients remain largely supportive. Corticosteroids provided symptomatic relief in some cases, while antifibrotic agents like nintedanib and pirfenidone were used off-label in selected patients with progressive fibrosis. However, further randomized trials are necessary to establish efficacy. Pulmonary rehabilitation, vaccination, and careful follow-up remain the cornerstones of post-COVID pulmonary care [4].

In conclusion, COVID-19-induced pulmonary fibrosis is a significant contributor to long-term morbidity. This study highlights the chronic nature of fibrotic lung changes in COVID-19 survivors and emphasizes the importance of long-term follow-up, early risk stratification, and ongoing research into effective treatment strategies [5].

Conclusion

This multi-center prospective study highlights the persistent burden of pulmonary fibrosis in a subset of post-COVID-19 patients, revealing variable patterns of disease stabilization, improvement, or progression over time. The findings underscore the importance of early identification and long-term monitoring of individuals at risk for fibrotic lung disease. Furthermore, the study advocates for the development of targeted management strategies, including pulmonary rehabilitation and potential antifibrotic therapy, to improve clinical outcomes and quality of life in affected individuals. As the world continues to manage the aftermath of the COVID-19 pandemic, understanding and addressing the sequelae of pulmonary fibrosis will be critical to optimizing long-term respiratory health.

References

  1. George PM, Barratt SL, Condliffe R, et al. Respiratory follow-up of patients with COVID-19 pneumonia. Thorax. 2020;75(11):1009-1016.

    2. Indexed at, Google Scholar, Cross Ref

  2. Myall KJ, Mukherjee B, Castanheira AM, et al. Persistent post–COVID-19 interstitial lung disease: An observational study of corticosteroid treatment. Ann Am Thorac Soc. 2021;18(5):799-806.

    3. Indexed at, Google Scholar, Cross Ref

  3. Guler SA, Ebner L, Beigelman C, et al. Pulmonary function and radiological features four months after COVID-19: First results from the national prospective observational Swiss COVID-19 lung study. Eur Respir J. 2021;57(4):2003690.

    4. Indexed at, Google Scholar, Cross Ref

  4. McGroder CF, Zhang D, Choudhury MA, et al. Pulmonary fibrosis 4 months after COVID-19 is associated with severity of illness and blood leucocyte telomere length. Thorax. 2021;76(12):1242-1245.

    5. Indexed at, Google Scholar, Cross Ref

  5. Naik S, Moore JB, Peters MJ. COVID-19 and pulmonary fibrosis: A potential role for antifibrotic therapy?. Lancet Respir Med. 2020;8(8):807-815.

    6. Indexed at, Google Scholar, Cross Ref

Get the App